Literature DB >> 7874377

Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.

G Gatti1, E Perucca.   

Abstract

The plasma concentrations of free (unconjugated) and conjugated silybin after intake of a single oral dose of a lipophilic silybin-phospatidylcholine complex (silipide, 80 mg expressed as silybin equivalents) were evaluated in 12 healthy volunteers by using a sensitive and specific HPLC method. Free silybin concentrations reached a peak of 141 +/- 31 ng/ml (mean +/- SEM) at 2.4 hours after dosing and declined thereafter with a half-life of about 2 hours. Peak concentrations of conjugated silybin were greater (255 +/- 35 ng/ml) and occurred at a later time (about 3.8 hours). The elimination of conjugated drug tended to be slower than that of free drug. AUC values for conjugated sylibin were about three-fold greater than those of free drug. It is concluded that after oral intake of silipide, silybin undergoes extensive conversion to conjugated derivative(s) which are retained in the circulation at relatively large concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874377

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  14 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

3.  The gallic acid-phospholipid complex improved the antioxidant potential of gallic acid by enhancing its bioavailability.

Authors:  Sauvik Bhattacharyya; Sk Milan Ahammed; Bishnu Pada Saha; Pulok K Mukherjee
Journal:  AAPS PharmSciTech       Date:  2013-06-26       Impact factor: 3.246

Review 4.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Silymarin for HCV infection.

Authors:  Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Antivir Ther       Date:  2012-09-25

6.  An Overview of Ultraviolet B Radiation-Induced Skin Cancer Chemoprevention by Silibinin.

Authors:  Rahul Kumar; Gagan Deep; Rajesh Agarwal
Journal:  Curr Pharmacol Rep       Date:  2015-06-01

Review 7.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

Review 9.  Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Authors:  Stephen J Polyak; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425

10.  Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Authors:  Sonia R Miranda; Jin Kyung Lee; Kim L R Brouwer; Zhiming Wen; Philip C Smith; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-08-07       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.